Article Text

Download PDFPDF

Response to: ‘ Correspondence on ‘Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension’’ by Iudici et al
Free
  1. Ekkehard Grünig1,2,
  2. Nicola Benjamin1,2,
  3. Panagiota Xanthouli1,2,
  4. Suzana Jordan3,
  5. Nicklas Milde1,2,
  6. Alberto Marra4,
  7. Norbert Blank5,
  8. Benjamin Egenlauf1,2,
  9. Matthias Gorenflo6,
  10. Satenik Harutyunova1,2,
  11. Hanns-Martin Lorenz5,
  12. Christian Nagel1,2,7,
  13. Vivienne Theobald1,2,
  14. Mona Lichtblau8,
  15. Charlotte Berlier8,
  16. Silvia Ulrich8,
  17. Oliver Distler3
  1. 1Centre for Pulmonary Hypertension, Thoraxklinik-Heidelberg gGmbH at Heidelberg University Hospital, Heidelberg, Germany
  2. 2Translational Lung Research Center Heidelberg (TLRC), Member of the German Center for Lung Research, Heidelberg, Germany
  3. 3Department of Rheumatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland
  4. 4IRCCS SDN Naples, Naples, Italy
  5. 5Department of Internal Medicine 5: Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany
  6. 6Department of Pediatric Cardiology, University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany
  7. 7Lung Centre, Klinikum Mittelbaden gGmbH, Baden-Baden, Baden-Württemberg, Germany
  8. 8Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland
  1. Correspondence to Nicola Benjamin, Centre for pulmonary hypertension, Thoraxklinik-Heidelberg gGmbH, 69126 Heidelberg, Germany; nicola.benjamin{at}med.uni-heidelberg.de

Statistics from Altmetric.com

In their correspondence Iudici et al1 highlight three important aspects which are to consider in the interpretation of survival data when introducing new thresholds of an early stage of disease.2 They point out, that lead-time bias, length-time bias as well as increasing numbers of patients have to be considered for the new haemodynamic definition of pulmonary arterial hypertension (PAH).

In studies investigating the effect of systematic PAH screening programmes on survival in patients with systemic sclerosis, part of the effect of an increased survival may be attributed to lead-time bias and length-time bias.3 4

We agree with Iudici et al that lead-time bias is an important aspect when introducing a new definition of a disease, which includes patients at a less severe stage. This becomes especially important for screening programmes, as survival of screened patients who are diagnosed at early disease stages may implicitly be better compared with patients with a more severe disease.

In our study we analysed the frequency of PAH in patients with systemic sclerosis when applying the new PAH definition according to the suggestion from the World Symposium on pulmonary hypertension in Nice 2018. According to a large meta-analysis of haemodynamic data of healthy people, a pulmonary vascular resistance (PVR) >2 Wood Units (WU) can already be seen as abnormal in most age levels, with regard to mean PVR +2 standard deviations.5 We introduced the threshold of a PVR of 2 WU to investigate, whether these patients already present with pathological characteristics of pulmonary vascular disease.

We would like to emphasise that the objective of our study was not to present an advantage of early diagnosis, as our data does not provide enough information to investigate this question. We aimed to show, that even patients with less severe changes of pulmonary vascular haemodynamics already showed typical characteristics of pulmonary vascular disease and an impaired survival, though part of these patients will never develop manifest PAH. The higher the lead-time bias with increased survival-time for these patients would be, the less pronounced would be the difference of survival between patients with PVR ≥2 WU compared with PVR <2 WU. A difference of survival between these two groups therefore supports the hypothesis, that patients with PVR ≥2 WU are already compromised.

Prediction of manifest PAH is, as Iudici et al correctly state, complicated and multifactorial. Statistical models have not yet been implemented and assumptions may possibly be unrealistic. Though determining factors for the development of manifest PAH have already been identified in PAH, prediction of the disease is still not straight-forward and needs further investigation. Furthermore, considering several known determining factors of survival or progression to manifest disease in this cohort would most likely lead to overfitted models, as simple sizes in our cohort were restricted due to the rarity of both systemic sclerosis and PAH. However, the sensitivity analysis of an age-adjusted Cox regression which we performed in our study confirmed our findings of a significant impact of PVR on survival. As the applied risk stratification models also seemed to work better with patients with PVR ≥2 WU, but not for PVR <2 WU, their use in clinical practice would also be appropriate in this patient group.

Therapeutic indications in a cohort of patients with mild pulmonary vascular disease who usually would only be diagnosed with manifest PAH due to a change in definition should be carefully investigated, as data on PAH-targeted treatment in these patients is currently lacking. In this regard, the meaning of a diagnosis of mild PAH should be handled with care regarding its therapeutic consequences and impact on the patient.

References

View Abstract

Footnotes

  • Handling editor Josef S Smolen

  • Contributors All authors drafted, read and approved the manuscript and agree to all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests PX has received personal fees from MSD and OMT. AM has received personal fees from Bayer, outside the submitted work. NB has received consulting fees, speaker fees and/or honoraria from MSD, GSK, Actelion and Bayer Vital. BE received travel fees, consulting fees, speaking fees and/or honoraria from Actelion, MSD, Bayer and OMT (less than US$10 000 each). MG serves on an advisory Board for Bayer AG and receives lecture fees from Pfizer, MSD and Actelion Pharmaceuticals. SH has received personal fees from Bayer, MSD, Actelion and GSK, outside the submitted work. H-ML has received consulting fees, speaking fees and/or honoraria from AbbVie, BMS, Pfizer, Cellgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, AstraZeneca and Lilly (less than US$10 000 each) and research support from AbbVie, MSD, BMS, Cellgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, AstraZeneca, Lilly, Baxter, SOBI, Biogen, Actelion, Bayer Vital, Shire, Octapharm, Sanofi, Hexal, Mundipharm and Thermo Fisher. CN has received consulting fees, speaking fees and/or honoraria from Actelion, MSD, Boehringer, Novartis, Bayer and AstraZeneca (less than US$10 000 each). CB received travel support from Actelion SA and Orpha Swiss and speakers’ fee from MSD. SU received grants from the Swiss National Science foundation and the Zurich Lung League, travel support and speakers’ fees from Actelion SA, Switzerland, Bayer SA, Germany, MSD, Switzerland and Orpha Swiss. EG has received grants and personal fees from Actelion, Bayer AG and MSD; grants from GSK, Novartis and United Therapeutics; and personal fees from SCOPE, OrPha Swiss GmbH and Zurich Heart House (less than US$10 000 each). NB received speaker fees from Actelion pharmaceuticals, Bayer HealthCare and MSD. OD has received grants and personal fees from research consultancies from AM, Acceleron Pharma, Amgen, AnaMar, Bayer, Beacon Discovery, Boehringer Ingelheim, Catenion, CSL Behring, ChemomAb, Ergonex, GSK, Inventiva, Italfarmaco, iQone, iQvia, Lilly, medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Novartis, Pfizer, Roche, Sanofi, Blade Therapeutics, Glenmark Pharmaceuticals, Target Bio Science and UCB, outside the submitted work, to investigate potential treatments of scleroderma and its complications. In addition, OD has a patent mir-29 for the treatment of systemic sclerosis issued (US8247389, EP2331143).

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles